

Session Summary

March 06, 2026

Report Generated	March 06, 2026 at 00:42
User	
Organization	AVTI
Conversation Thread	
Summary Scope	~5 page(s)
Focus Areas	Medical writer team (1 senior lead, 1 junior)

Executive Summary

Internal Team Handoff Document

Project: Portugal HIV Standard of Care and Healthcare-System Improvement

Intended Receiving Team: Medical Writer Team

Team Structure Assumed: 1 Senior Lead, 1 Junior Writer

1. Purpose of This Handoff

This document is intended to allow a medical writing team that was **not present in the session** to continue the work without loss of context. It captures:

- what has already been completed,
- what has been verified,
- what remains open,
- the verification logic used,
- and the next actions required to convert the session outputs into usable internal deliverables.

The work is currently oriented toward a **Portugal-specific HIV standard-of-care and healthcare-system improvement opportunity**, with a likely **DGS-facing RFP or proposal context**.

2. What Was Completed

A. Core evidence and strategic work completed in session

Workstream	Status	Output Produced	Usefulness for Next Team
Portugal HIV landscape review.	Completed.	Country-level analysis of epidemiology, treatment environment, prevention model, unmet need, and healthcare-system context.	Use as the factual basis for any narrative, executive summary, or background section.
Market access and payer review.	Completed.	Portugal payer-system deep dive covering INFARMED, SiNATS, access logic, hospital spend visibility, and implementation implications.	Use for payer, value, access, and institutional sections.

Workstream	Status	Output Produced	Usefulness for Next Team
News and government activity scan.	Completed.	Review of recent DGS, SPMS, INFARMED, and policy developments relevant to HIV treatment and prophylaxis.	Use for “current context,” “why now,” and system-readiness framing.
Phase 2 strategic foundation.	Completed.	Strategic foundation for a DGS project on HIV standard of care and healthcare-system improvement.	Use to shape high-level proposal logic.
Phase 3 tactical framework.	Completed.	Tactical programme structure, workstreams, deliverables, and sequencing.	Use to build workplan tables and activity descriptions.
Phase 4 extended tactical planning.	Completed.	Detailed work package, deliverables, governance, resource, and implementation structure.	Use directly in proposal drafting or internal scope documents.
Historical precedent finder.	Completed.	Structured comparison of analogous public-system HIV programmes with empirical patterns extracted.	Use to justify delivery assumptions and explain why specific design choices are recommended.
Monte Carlo multi-plan simulation.	Completed.	1,000-iteration simulation across five plan variants using `mc_rng.py`; variant ranking generated.	Use to support internal decision-making on proposal structure.
Plan optimization.	Completed.	Refactored recommendation for the strongest bid architecture.	Use as the current working recommendation.
Executive session summary.	Completed.	Strategic summary of the full session.	Use as a high-level briefing note for leadership.

3. Current Working Conclusion

Recommended project architecture

The strongest working recommendation from the session is:

- 1 Use a Data and Governance Backbone as the core proposal architecture.**
- 2 Use Pilot-to-Scale Demonstrators as the preferred implementation layer.**
- 3 Embed prevention and PrEP redesign as a module within the backbone.**
- 4 Do not lead with a full one-step integrated transformation.**

What this means operationally

Item	Current Working Position
Default proposal shape.	Backbone-first, phased, controlled, measurable.
Prevention content.	Important, but should sit inside a stronger governance and implementation shell.
National rollout language.	Should be softened and reframed as phased implementation.
Transformation ambition.	Keep in roadmap language, not as the base delivery promise.
Best-supported variant from simulation.	Data and Governance Backbone.
Best stretch option.	Pilot-to-Scale Demonstrators.
Weakest option.	Full Integrated Transformation in one step.

4. What Was Found -- Verified Facts

A. Portugal HIV landscape

Topic	Verified Fact	Why It Matters
HIV burden.	Portugal continues to report a meaningful annual number of new HIV diagnoses.	HIV remains a live and defensible national public-health priority.
Late diagnosis.	Late diagnosis remains a major unresolved issue in Portugal.	This is one of the strongest justification points for a healthcare-system improvement project.
Care continuum.	Treatment uptake and viral suppression are strong once patients are diagnosed and engaged in care.	The main problem is not downstream treatment effectiveness; it is earlier diagnosis, prevention reach, and system navigation.
HIV-2.	HIV-2 remains clinically relevant in Portugal.	This makes Portuguese HIV planning less generic than in many other European settings.

B. Prevention and standard of care

Topic	Verified Fact	Why It Matters
PrEP governance.	Portugal updated its PrEP guidance and enabled electronic prescribing and community-pharmacy dispensing.	Prevention access is no longer structurally confined to specialist pathways.
Prevention materials.	DGS continues to support broader prevention activity through official distribution measures.	The policy environment remains combination-prevention oriented, not treatment-only.
Standard of care trend.	European standards continue to reinforce integrated prevention, testing, treatment initiation, and chronic-care management.	Supports a broader definition of standard of care for the DGS project.

C. Payer and system context

Topic	Verified Fact	Why It Matters
Institutional structure.	DGS, INSA, INFARMED, SPMS, and SNS delivery structures all matter in the Portuguese HIV system.	The project must be framed as a multi-institutional public-system effort.
HTA and access.	INFARMED and SiNATS are central to public-value and access logic.	Any claims about healthcare-system improvement should acknowledge payer and institutional realities.
Budget visibility.	HIV remains a visible category within Portuguese hospital medicine expenditure.	Makes efficiency, continuity, and service design relevant, not just clinical outcomes.

D. Strategic design findings

Topic	Verified / Supported Finding	Why It Matters
Historical analogues.	Comparable programmes succeeded when governance, measurement, training, and channel activation were built in early.	Supports a practical, implementation-oriented proposal design.
Simulation result.	The best balanced project architecture was the Data and Governance Backbone model.	This is the current preferred internal recommendation.
Risk finding.	The broadest one-step transformation plan was overexposed to timing and execution risk.	Avoid using this as the base narrative.

5. What Remains Open

Open gaps that still need targeted follow-up

Gap	Why It Is Still Open	Impact if Left Unresolved	Priority
Site-level pathway variation across ULS.	Public sources do not provide sufficient local workflow detail.	Weakens operational specificity in the proposal.	High.
Local maturity of community-pharmacy and community-based PrEP implementation.	National policy is visible, but real local execution data remain incomplete.	Risks overstating service readiness.	High.
Full treatment-modality uptake detail in Portugal.	Publicly available patient-share or site-share data are incomplete.	Limits any product- or modality-specific narrative.	Medium.
Exact procurement expectations from DGS for this specific opportunity.	No formal tender pack or specification was available in-session.	Scope, deliverables, and tone may need adjustment once the real RFP is seen.	High.
Data architecture feasibility across institutions.	It is not yet clear what DGS, INSA, SPMS, and ULS can practically supply in a project timeline.	A dashboard or KPI promise could become unrealistic if not validated.	High.

Gap	Why It Is Still Open	Impact if Left Unresolved	Priority
Equity performance under current prevention pathways.	Formal access reforms are recent and detailed subgroup reporting is still limited.	May leave the proposal insufficiently specific on underserved populations.	Medium to High.

6. Verification Logic Used

Verification rules applied in-session

Rule	How It Was Applied
Prioritize official and peer-reviewed sources.	DGS, INSA, SPMS, INFARMED, ECDC, EACS, and peer-reviewed studies were prioritized over commentary or secondary summaries.
Separate verified fact from inference.	Epidemiology, policy changes, and institutional structures were treated as verified only when grounded in primary or peer-reviewed sources. Strategic recommendations were explicitly treated as derived judgments.
Use live search for current-state claims.	Policy and system context with potential recency sensitivity were checked against current official sources.
Treat uncertainty explicitly.	When Portuguese local implementation status could not be fully confirmed, the point was left open rather than overstated.
Use empirical calibration for planning logic.	Historical programme analogues were used to calibrate plan assumptions, not to replace Portugal-specific reasoning.
Use actual simulation for plan comparison.	The multi-plan Monte Carlo was executed in code using `mc_rng.py`, not estimated narratively.

Practical interpretation for the receiving team

Do **not** upgrade any currently open point into a factual statement unless:

- 1 a new official source has been located, or
- 2 a stakeholder confirmation has been obtained and documented internally.

7. What the Receiving Medical Writing Team Should Assume

Safe assumptions to carry forward

Item	Working Assumption
Core narrative.	Portugal HIV care is strong once patients are diagnosed, but earlier diagnosis, prevention reach, and operational coordination remain the main system challenges.

Item	Working Assumption
Project framing.	This is best framed as a public-health and healthcare-system improvement project, not a therapy-optimization or product-framed project.
Proposal design.	Governance, KPI architecture, readiness, and phased implementation should be treated as central, not supplementary.
Prevention role.	Prevention and PrEP should remain important, but within a broader system design.
Tone.	All outputs should remain institutionally credible, non-promotional, and operationally realistic.

Unsafe assumptions to avoid

Do Not Assume	Why
That all local Portuguese sites are equally ready for decentralized prevention pathways.	This has not been established.
That DGS wants a broad transformation package by default.	The actual procurement language has not been seen.
That public policy change automatically equals mature field implementation.	Historical and Portuguese evidence both argue against that assumption.
That treatment optimization is the main strategic story.	The stronger story is service design, prevention activation, and system performance.

8. Prioritised Next Steps for the Receiving Team

Priority 1 -- Immediate

Task	Owner	Output	Deadline Priority
Convert the optimized recommendation into a one-page internal proposal architecture.	Senior lead.	One-page bid architecture document.	Immediate.
Build a clean source matrix from the verified session materials.	Junior writer.	Source tracker with topic, claim, source type, date, and status.	Immediate.
Draft a "Portugal HIV project background" section using verified facts only.	Junior writer, reviewed by senior.	Reusable background narrative for proposals and decks.	Immediate.
Draft a "Why now / why DGS / why this shape" section.	Senior lead.	Executive rationale paragraph set.	Immediate.

Priority 2 -- Short-term follow-up

Task	Owner	Output	Deadline Priority
Convert Phase 3 and Phase 4 outputs into proposal-ready workplan tables.	Senior lead.	Bid-ready methodology and workplan section.	High.
Build a gap-closure list for open items requiring direct validation.	Junior writer.	Validation tracker.	High.
Create a version-controlled deliverables register.	Junior writer.	Deliverables table with status and dependencies.	High.
Draft an equity subsection for the proposal.	Senior lead with junior support.	Targeted section on underserved populations and access variation.	High.

Priority 3 -- Validation before external-facing drafting

Task	Owner	Output	Deadline Priority
Validate local implementation assumptions for PrEP, pharmacy, and community pathways.	Senior lead to coordinate; junior to document.	Internal assumptions memo with evidence status.	High.
Confirm whether DGS procurement language is available.	Senior lead.	Procurement status note.	High.
Stress-test dashboard and KPI promises against realistic data availability.	Senior lead.	KPI feasibility note.	High.

9. Suggested Division of Work

Medical Writer Team: 1 Senior Lead, 1 Junior

Role	Recommended Responsibilities
Senior lead.	Own narrative architecture, proposal framing, strategic consistency, gap prioritization, and final quality control.
Junior writer.	Own source tracking, evidence table maintenance, first-draft factual sections, version control, and document hygiene.

Recommended working split

Work Item	Senior Lead	Junior Writer
Proposal framing and structure.	Lead.	Support.
Verified source log.	Review.	Lead.
Portugal landscape background.	Review and refine.	Draft.
Payer and government context.	Draft / refine.	Evidence support.
Workplan and deliverables tables.	Lead.	Format and consistency support.
Open-gap validation tracker.	Direct.	Build and maintain.
Final internal handoff to leadership.	Lead.	Support.

10. Recommended Immediate Deliverables to Prepare Next

Deliverable	Purpose	Status
Internal source matrix.	Prevent evidence drift and unsupported claims.	Not yet assembled as a formal tracker.
Proposal skeleton.	Turn session outputs into usable drafting structure.	Not yet assembled as one integrated draft.
Validation tracker.	Capture what is still open and who needs to verify it.	Not yet formalized.
Executive one-pager.	Brief internal stakeholders quickly.	Can be created directly from existing outputs.
Bid-ready methodology section.	Convert Phase 3 and Phase 4 into formal proposal language.	Partially done conceptually; not yet in final bid format.

11. Final Handoff Instruction

Receiving team should proceed as follows

- 1 Treat the current optimized architecture as the active working recommendation.**
- 2 Do not expand scope back toward one-step full transformation unless new sponsor guidance explicitly supports it.**
- 3 Use only verified facts in background and context sections.**
- 4 Track all open assumptions in a formal validation log.**
- 5 Prepare the next internal draft around four anchors:**
 - Portugal HIV baseline.
 - Why system improvement is needed now.
 - Why the proposed architecture is the strongest fit.

- What the delivery model and outputs look like.

Notes

- This handoff is designed for operational continuity, not executive presentation.
- It assumes no prior exposure to the session.
- The most useful follow-on artifact would be a **proposal drafting pack** containing:

- 1 source matrix,
- 2 validated claims list,
- 3 proposal skeleton,
- 4 workplan tables, and
- 5 open-gap tracker.

References:

- Internal vector materials retrieved via file_search:
 - comparison_guide_similarity_engine.json.
 - pillars_v2.json.
 - stakeholder_taxonomy_v2.json.
 - metrics_v2.json.
 - bd_calibration_package.txt / BD_CALIBRATION_PACKAGE.md.
 - mc_rng.py.
- Portugal HIV and public-health context:
 - DGS / INSA. Infecção por VIH em Portugal 2025.
<https://repositorio.insa.pt/entities/publication/c43d3502-8bf9-4a82-8fff-ea1c315d831f/full>
 - DGS. Summary page on new HIV cases and trends.
<https://www.dgs.pt/em-destaque/novos-casos-de-infecao-por-vih-diminuem-35-desde-2015.aspx>
 - DGS. Norma 001/2024 - Profilaxia de Pré-Exposição ao VIH.
<https://www.dgs.pt/normas-orientacoes-e-informacoes/normas-e-circulares-normativas/norma-001-2024-profilaxia-de-pre-exposicao-ao-vih-de-22-03-2024-pdf.aspx>
 - DGS. Informação 03/2025 - Material de prevenção da transmissão por via sexual do VIH e IST.
<https://www.dgs.pt/normas-orientacoes-e-informacoes/informacoes/informacao-n-0032025-de-16042025-distribuicao-nas-unidades-de-saude-de-material-de-prevencao-da-transmissao-por-via-sexual-do-virus-da-imunodeficiencia-humana-vih-e-infecoes-sexualmente-transmissiveis-ist-pdf.aspx>
- Portuguese delivery, access, and payer context:
 - SPMS. Já está disponível prescrição eletrónica da PrEP.
<https://www.spms.min-saude.pt/2024/07/ja-esta-disponivel-prescricao-eletronica-da-prep/>
 - SPMS. PEM.
<https://www.spms.min-saude.pt/tema/pem/>
 - INFARMED. Avaliação de tecnologias de saúde.
<https://www.infarmed.pt/web/infarmed/entidades/dispositivos-medicos/avaliacao-de-tecnologias-de-saude>
 - INFARMED. Acesso à inovação terapêutica em Portugal acima da média europeia.
https://www.infarmed.pt/web/infarmed/profissionais-de-saude/-/journal_content/56/15786/11208137
 - INFARMED. Relatório - Agosto 2025.
<https://www.infarmed.pt/documents/15786/11273149/agosto/a8e94752-e064-8e27-bea0-d6a1983590ae?version=1.0>
- European standards and broader HIV care context:
 - ECDC. ECDC releases new standards to improve HIV prevention and care.
<https://www.ecdc.europa.eu/en/news-events/ecdc-releases-new-standards-improve-hiv-prevention-and-care>
 - ECDC. ECDC/EACS standards of HIV care.
<https://www.ecdc.europa.eu/en/infectious-disease-topics/hiv-infection-and-aids/prevention-and-treatment/ecdceacs-standards-hiv>
 - EACS. EACS Guidelines.
<https://www.eacsociety.org/guidelines/eacs-guidelines/>
- Historical precedent and empirical calibration sources:

- GOV.UK. HIV Action Plan for England, 2025 to 2030.
<https://www.gov.uk/government/publications/hiv-action-plan-for-england-2025-to-2030/hiv-action-plan-for-england-2025-to-2030>
- Sexually Transmitted Infections. HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC7616873/>
- NSW Health. NSW HIV Strategy 2021-2025.
<https://www.health.nsw.gov.au/endinghiv/Publications/nsw-hiv-strategy-2021-2025.pdf>
- Public Health Scotland. HIV in Scotland update to 31 December 2024.
<https://publichealthscotland.scot/publications/hiv-in-scotland-update-to-31-december-2024/>
- Process evaluation of Scotland's nationally implemented PrEP programme.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC10561843/>
- France nationwide observational study of PrEP rollout, 2016-2021.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC9386455/>
- PubMed. Effect of extending PrEP initiation to primary care settings: a nationwide cohort study in France.
<https://pubmed.ncbi.nlm.nih.gov/40215984/>

All outputs are AI-assisted under GDPR, EMA, and jurisdictional transparency frameworks. They do not constitute legal, medical, or financial advice. Outputs require human validation. Data processed with consent, encryption, and audit traceability.

References

#	Description	Full URL
1	repositorio.insa.pt	https://repositorio.insa.pt/entities/publication/c43d3502-8bf9-4a82-8fff-ea1c315d831f/full
2	www.dgs.pt	https://www.dgs.pt/em-destaque/novos-casos-de-infecao-por-vih-diminuem-35-desde-2015.aspx
3	www.dgs.pt	https://www.dgs.pt/normas-orientacoes-e-informacoes/normas-e-circulares-normativas/norma-001-2024-profilaxia-de-pre-exposicao-ao-vih-de-22-03-2024-pdf.aspx
4	www.dgs.pt	https://www.dgs.pt/normas-orientacoes-e-informacoes/informacoes/informacao-n-0032025-de-16042025-distribuicao-nas-unidades-de-saude-de-material-de-prevencao-da-transmissao-por-via-sexual-do-virus-da-imunodeficiencia-humana-vih-e-infecoes-sexualmente-transmissiveis-ist-pdf.aspx
5	www.spms.min-saude.pt	https://www.spms.min-saude.pt/2024/07/ja-esta-disponivel-prescricao-eletronica-da-prep/
6	www.spms.min-saude.pt	https://www.spms.min-saude.pt/tema/pem/
7	www.infarmed.pt	https://www.infarmed.pt/web/infarmed/entidades/dispositivos-medicos/avaliacao-de-tecnologias-de-saude
8	www.infarmed.pt	https://www.infarmed.pt/web/infarmed/profissionais-de-saude/-/journal_content/56/15786/11208137
9	www.infarmed.pt	https://www.infarmed.pt/documents/15786/11273149/agosto/a8e94752-e064-8e27-bea0-d6a1983590ae?version=1.0
10	www.ecdc.europa.eu	https://www.ecdc.europa.eu/en/news-events/ecdc-releases-new-standards-improve-hiv-prevention-and-care
11	www.ecdc.europa.eu	https://www.ecdc.europa.eu/en/infectious-disease-topics/hiv-infection-and-aids/prevention-and-treatment/ecdc-eacs-standards-hiv
12	www.eacsociety.org	https://www.eacsociety.org/guidelines/eacs-guidelines/
13	www.gov.uk	https://www.gov.uk/government/publications/hiv-action-plan-for-england-2025-to-2030/hiv-action-plan-for-england-2025-to-2030
14	pmc.ncbi.nlm.nih.gov	https://pmc.ncbi.nlm.nih.gov/articles/PMC7616873/
15	www.health.nsw.gov.au	https://www.health.nsw.gov.au/endinghiv/Publications/nsw-hiv-strategy-2021-2025.pdf
16	publichealthscotland.scot	https://publichealthscotland.scot/publications/hiv-in-scotland-update-to-31-december-2024/
17	pmc.ncbi.nlm.nih.gov	https://pmc.ncbi.nlm.nih.gov/articles/PMC10561843/
18	pmc.ncbi.nlm.nih.gov	https://pmc.ncbi.nlm.nih.gov/articles/PMC9386455/
19	pubmed.ncbi.nlm.nih.gov	https://pubmed.ncbi.nlm.nih.gov/40215984/